Cardiac autonomic neuropathy in patients with SGA-treated schizophrenia: a randomized controlled trial of 30 weeks’ treatment with semaglutide

Abstract Background Individuals with schizophrenia suffer from reduced life expectancy, primarily due to obesity-related metabolic disorders and cardiovascular disease (CVD). The presence of cardiac autonomic neuropathy (CAN) may contribute to CVD, but CAN is reversible, and it may improve following...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Ashok Ainkaran Ganeshalingam, Nicolai Gundtoft Uhrenholt, Sidse Arnfred, Peter Gæde, Andreas Kristian Pedersen, Niels Bilenberg, Jan Frystyk
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BioMed Central 2026-01-01
Schriftenreihe:	Cardiovascular Diabetology. Endocrinology Reports
Schlagworte:	Schizophrenia Prediabetes Prevention Cardiovascular autonomic neuropathy Antipsychotic treatment Obesity
Online-Zugang:	https://doi.org/10.1186/s40842-025-00258-0
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!